CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication

TARRYTOWN, N.Y. and PARIS, March 1, 2019 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ... Biopharmaceuticals, Regulatory Regeneron Pharmaceuticals, Sanofi, Dupixent, dupilumab, asthma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news